WO1994003174A1 - Treatment of dentoalveolar infections with taurolidine and/or taurultam - Google Patents
Treatment of dentoalveolar infections with taurolidine and/or taurultam Download PDFInfo
- Publication number
- WO1994003174A1 WO1994003174A1 PCT/GB1993/001607 GB9301607W WO9403174A1 WO 1994003174 A1 WO1994003174 A1 WO 1994003174A1 GB 9301607 W GB9301607 W GB 9301607W WO 9403174 A1 WO9403174 A1 WO 9403174A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- taurolidine
- dental
- taurultam
- infection
- infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention is concerned with the combatting tooth and gum infections, in particular severe dental infections which are located within the alveolar region of the jaw.
- the complex aetiology of oral infections results in the observation of widely variable resistance patterns following administration of conventional oral antibacterial preparations. Such preparations may also not be sufficiently active against some of the pathogenic organisms present. There is thus a need for a wide-spectrum agent to treat such mixed infections. Administration of an agent which is ineffective against some of the bacteria present will result in proliferation of the resistant bacterial species and complete elimination of the infection may not be achieved.
- the types of bacteria present in dentoalveolar infections include aerobes such as Streptococcus viridans qr. , Streptococcus qr C. , Corynebacterium spp.. Neisseria spp and Haemophilus influenzae.
- Anaerobes which are also commonly present include Peptococcus spp. , Bacteroides spp. and Furobacterium spp.
- Conventional treatments include bactericidal agents such as chlorophenol-camphor-menthol, chlorhexidine and antibiotics such as chlorteracyclin and tetracinolon.
- bactericidal agents such as chlorophenol-camphor-menthol, chlorhexidine and antibiotics such as chlorteracyclin and tetracinolon.
- antibiotics such as chlorteracyclin and tetracinolon.
- conventional agents require a relatively prolonged period of treatment to be completely effective.
- Chlortetracycline and Democlocycline are considered inadvisable because of their instability and increased toxicity. It has been shown in this connection, that formation of the highly nephro-toxic anhydro-4-epitetracyclin-hydrochloride occurs in older Tetracycline preparations.
- the aminoglycoside antibiotic Neomycin may only be applied locally because of its extreme nephrotoxic, ototoxic and muscle relaxant properties.
- resorption can occur when the ectoderm is damaged (i.e. marginal and apical parodontitis, mucous-membrane ulceration) and repeated usage can lead to analogous side-effects.
- the withdrawal of this preparation was suggested in 1975.
- the quinoline derivative Aminoquinuride (Surfen) which increases the spectrum of Neomycin, has not been investigated sufficiently and its effectivity is controversial.
- Synthetic corticosteroid derivatives like Prednisolone and Triamcinolone are intended to supercede the role of an analgesic in combination preparations. Although their strong anti-inflammatory and anti ⁇ allergic properties make for a quick reduction of pain this would always be accompanied by an immune separation which arises out of a comprehensive inhibition mesenchy al reaction. As well as an inhibition of the lympho-reticular system, damage also arises to the DNA- repair and mitosis capability which can lead to tissue atrophy. The fibrinogen concentration in the plasma is reduced by simultaneously strengthened fibrinolysis.
- Chlorophenol-Ca phor and Chlorophenol- Camphor-Menthol solutions are often recommended for root canal instillation and no significantly higher or stronger pain sensation following instillation in the pulpen cavity has been reported as against comparative clinical experiments, the high toxic potential is undisputed. In animal experiments strong tissue toxic reactions have been observed in the form of inflammation and necrosis formation.
- Chlorhexidine which has proved itself in extensive experimental and clinical studies as a broad spectrum anti-microbial, is also cell damaging. In tests carried out on human desmodontal fibroblasts, accelerated ageing and a cytopathological effect were demonstrated. The release of p-chloroaniline as a possible by-product of chlorohexidine, which is suspected of causing mutation and of being carcinogenic, is often denied.
- taurolidine is effective against oral infections, especially those that are located within the infrastructure of the jaw, but exhibits a much reduced level of side-effects and provides effective relief in a shorter period.
- taurolidine is a synthetic derivative of the naturally occurring 2-aminoethane sulphonic acid, taurine.
- taurolidine is a potential anti ⁇ microbial substance, acting by a ethylol transfer mechanism, has been disclosed in GB 1,124,285. It is sold by Ed. Geistlich Sohne AG. under the registered Trade Mark 'Taurolin'.
- the antibacterial substance taurultam is closely related to taurolidine and, indeed, is formed during the methylol transfer reaction between taurolidine and target substances. It is also produced by Ed. Geistlich Sohne AG. Taurultam is slightly more water soluble than taurolidine but possesses fewer methylol transfer groupings.
- taurolidine compositions would be useful in combatting other, more severe dental infections such as gangrene, parodontitis and abscesses. Neither was it known that administration of a taurolidine composition was so much more effective as regards reducing the length of time and the dosage required for treatment.
- the present invention provides the use of taurolidine and/or taurultam in the preparation of an orally acceptable medicament for combatting severe dental infections or dental infection following dental surgery.
- the term "combatting” as used herein includes both therapeutic and prophylactic treatment.
- severe dental infections is used herein to refer to those infections which have become established in the interior of the jaw infrastructure, eg. dentoalveolar infections, such as gangrene, parodontitis or dental abscesses.
- parodontitis is an inflammatory reaction of the tissues surrounding a tooth and can be characterised by formation of periodontal pockets, pus formation, bone resorption, destruction of the periodontal ligament and tooth loss. Parodontitis is a different condition from parodontosis.
- TNF tumour necrosis factor
- taurolidine and/or taurultam can be used prophylactically following surgery such as implantation.
- Dental, mandibular or maxillofacial surgery is relatively common and varies from a complete restructing of the jaw bone, (for example following injury to that area) to replacement of a natural tooth with an artificial dentiform implant (false tooth) .
- Removal of a natural tooth may have occurred by accident, for example resulting from a blow to the face, or may be undertaken by surgical techniques made necessary by, for example, untreated decay of the tooth structure.
- the tooth socket is generally prepared by the dental surgeon.
- Usually a titanium implant is first located in the tooth socket, and then the false tooth proper is firmly attached to the titanium implant, conveniently by means of opposing screw threads so that the false tooth may be simply screwed into place.
- taurolidine and/or taurultam can be used prophylactically, for example by simple local application, to greatly reduce the incidence of post-operative infection.
- the present invention thus provides the use of taurolidine and/or taurultam in the preparation of an orally acceptable prophylactic medicament to prevent dental or gum infections, and in particular to prevent such infections following dental, andibular or maxillofacial surgery.
- compositions of taurolidine and/or taurultam which may be used to combat severe dental infections (as defined above) or as a prophylaxis include gels, emulsions, liquid gel or rinse solutions.
- compositions are new and comprise a further aspect of the present invention.
- One particular formulation for use in combatting tooth infections is an aqueous emulsion comprising taurolidine or taurultam in solution in the aqueous phase.
- the oily phase of such an emulsion can comprise a physiologically acceptable oil eg. a food -oil such as soya or arachis oil.
- One or more emulsifiers can be present, for example non-ionic emulsifiers such as glyceryl monostearate, fatty alcohols such as cetyl or yristyl alcohol, or lecithin.
- a thickening agent such as hydroxyethylcellulose (Natrosol 250 HHR) , carboxymethylcellulose, polyethylene glycol, sodium alginate, polyacrylic acid cross-linked by an alkyl ether of pentaerythritol or sucrose (Carbopol) or polyvinylpyrolidone is desirably added.
- hydroxyethylcellulose Naatrosol 250 HHR
- carboxymethylcellulose polyethylene glycol, sodium alginate
- polyacrylic acid cross-linked by an alkyl ether of pentaerythritol or sucrose (Carbopol) or polyvinylpyrolidone is desirably added.
- the advantage of such a formulation is delayed release of the taurolidine or taurultam when the formulation is introduced in the vicinity of the infection and resistance to elimination from the site of infection by saliva.
- the present invention further provides an orally acceptable composition, said composition comprising taurolidine and/or taurultam together with pharmaceutically acceptable excipients in the form of a liquid gel, rinse solution or as an emulsion.
- compositions according to the invention may be used either by themselves or in conjunction with surgery to combat the infection.
- One particularly useful aspect is the impregnation of a gauze strip with a taurolidine and/or taurultam- containing emulsion which can be applied to the affected area by the dentist or orthodontist.
- a taurolidine and/or taurultam containing gel is particular convenient for prophylactic use.
- a tube of the gel can be given to the patient who will then apply it to the affected area, as required, for example up to 6 times a day, depending on the extent of surgery and the strength of the gel.
- an orally acceptable composition according to the present invention will comprise 0.5 to 5% taurolidine by weight, preferably 1 to 3% by weight, or 0.75 to 7.5% by weight of taurultam, preferably 1.5 to 4.5%.
- the invention further provides a method of combatting severe dental infections (as defined herein) , said method comprising administering an orally acceptable taurolidine and/or taurultam-containing composition to the affected area of the patient.
- taurolidine and/or taurultam for combatting severe dental infections such as parodontitis, dental gangrene or abscesses and for the manufacture of dental compositions for such treatment.
- the liquid compositions of the invention are particularly adapted for combatting dentoalveolar infections, such as gangrene or abscesses, for example by introduction via a syringe into tooth canals or application at or near the site of infection for delayed release.
- dentoalveolar infections such as gangrene or abscesses
- Such liquid compositions include emulsions, as indicated hereinafter, which may be applied via an impregnated gauze strip overlying the infected area, as well as rinse solution which can be used in the treatment of gangrene, abscesses and perikornitis and liquid dental gels which can be introduced via a syringe in the treatment of gangrene, apical astitis and root canal treatment.
- Taurolidine has been tested for a number of orodental indications against therapy using conventional antibacterials. It could be seen that all target variables fell significantly more quickly under taurolidine medication than under conventional therapy. The total treatment time in the standard group was about 40% longer than in the taurolidine group. Moreover significantly less antibiotics and analgetics were required under taurolidine medication than under standard therapy. In contrast to most of the conventional preparations, which implicate a lot of side effects as irritation of smell and taste, discoloring of teeth and fillings, allergic reactions and histotoxicity with consecutive necroses, taurolidine only -shows slight pain for some minutes after application during the acute period of inflammation. The following study clearly demonstrates that treatment of severe dental infections using taurolidine compositions results in a marked decrease in the length of treatment time.
- test substances investigated were 4 different galenic presentation forms of the active component taurolidine and 4 conventional finished pharmaceuticals.
- AUREOMYCIN" ointment 3% (Cynamid-Novalis, Wolfratschausen/FRG) (1 g cont.: 30 mg chlorotetracycline, vaseline-anhydrous lanolin)
- DONTISOLON ointment Type M (Hoechst, Frankfurt Germany) (1 g cont.: 5 mg prednisolone, 2 mg neomycin HCL, 3 mg aminoquinuride 2HC1 3.5 H 2 0, excipients)
- Tables 1 and 2 show the antimicrobial therapy regimens defined for patient groups A (Taurolidine group) and B (Standard group) . It is evident, that the only difference, with the same quantity of substance applied in the same form, v/as the choice of " preparation.
- T represents "Taurolin" in the Table above.
- the score-level 5 (total) was given at the moment of complete remission and describes consequently the final point of treatment.
- Tables 4 and 5 show the course of the remission for the two therapy regimens.
- a superior effectiveness of taurolidine to the standard therapy was demonstrable for all 6 indications corresponding to a clinical relevant more rapid recovery (p ⁇ 0.0001).
- the standard deviations in the taurolidine group were generally smaller than the comparable values in the standard group. This is also a fact that allows the dentist a better estimation of the required treatment time. Any influence of the investigated modifying variables as age, sex, localisation of the lesion and optional antibiotic or analgetic administration on the process of recovery as well as on total treatment time could not be shown neither in the taurolidine nor in the standard group.
- TIME (days) TAUR. STANDARD TAUR. STANDARD TAUR. STANDARD TAUR. STANDARD
- TIME (days) TAUR. STANDARD TAUR. STANDARD TAUR. STANDARD TAUR. STANDARD
- Composition % (by weight)
- Composition % (by weight)
- Composition % (by weight)
- Composition % (by weight)
- Composition % (by weight)
- B add to A/C and homogenise. Heat to 70°C; D mix with heating to 70°C; add the fatty phase to the aqueous phase in an emulsifying device and emulsify; cool with stirring to 25°C;
- Composition % (by weight)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002141056A CA2141056C (en) | 1992-07-30 | 1993-07-29 | Treatment of dentoalveolar infections with taurolidine and/or taurultam |
EP93917947A EP0652753A1 (en) | 1992-07-30 | 1993-07-29 | Treatment of dentoalveolar infections with taurolidine and/or taurultam |
JP6505094A JPH07509483A (en) | 1992-07-30 | 1993-07-29 | Treatment of tooth and alveolar infections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929216155A GB9216155D0 (en) | 1992-07-30 | 1992-07-30 | Treatment of dentoalveolar infections |
GB9216155.3 | 1992-07-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US77012796A Continuation | 1992-07-30 | 1996-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994003174A1 true WO1994003174A1 (en) | 1994-02-17 |
Family
ID=10719520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/001607 WO1994003174A1 (en) | 1992-07-30 | 1993-07-29 | Treatment of dentoalveolar infections with taurolidine and/or taurultam |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0652753A1 (en) |
JP (1) | JPH07509483A (en) |
CA (1) | CA2141056C (en) |
GB (1) | GB9216155D0 (en) |
WO (1) | WO1994003174A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10510540A (en) * | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ,インコーポレーテッド | Irrigation solutions and methods for controlling pain, inflammation and convulsions |
EP0928187A1 (en) * | 1996-06-24 | 1999-07-14 | Bio-Safe Enterprises, Inc. | Antibacterial composition |
WO2000001391A1 (en) * | 1998-07-02 | 2000-01-13 | Biolink Corporation | Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof |
JP2000501729A (en) * | 1995-12-12 | 2000-02-15 | オメロス メディカル システムズ,インコーポレーテッド | Vascular irrigation solution and method for controlling pain, inflammation, convulsions and restenosis |
WO2001039763A2 (en) * | 1999-12-06 | 2001-06-07 | Rhode Island Hospital, A Lifespan Partner | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
US6753328B2 (en) | 2001-10-01 | 2004-06-22 | Rhode Island Hospital | Methods of inhibiting metastases |
WO2004058193A1 (en) * | 2002-12-20 | 2004-07-15 | 3M Espe Ag | Dental material containing bacteriostatic and/or bactericidal substances |
EP1442753A1 (en) * | 2003-02-03 | 2004-08-04 | Polaschegg, Hans-Dietrich, Dr.techn. | Composition for the prevention of indwelling device related infection |
JP2007031454A (en) * | 1994-12-12 | 2007-02-08 | Omeros Corp | Irrigation solution and method for inhibition of pain, inflammation and spasm |
US7479505B2 (en) | 1999-12-06 | 2009-01-20 | Geistlich Phama Ag | Use of taurolidine to treat tumors |
EP1797884A3 (en) * | 1999-12-06 | 2010-02-10 | Geistlich Pharma AG | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
WO2012042349A1 (en) * | 2010-09-27 | 2012-04-05 | Geistlich Pharma Ag | Antimicrobial dental care preparation |
US8933147B2 (en) | 2005-11-17 | 2015-01-13 | 3M Innovative Properties Company | Anti-microbial dental impression material |
US9339036B2 (en) | 2004-11-02 | 2016-05-17 | Nd Partners, Llc | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
US11738120B1 (en) | 2022-04-14 | 2023-08-29 | Cormedix Inc. | Synthesis of taurolidine, purity profiles and polymorphs |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972933A (en) * | 1998-01-08 | 1999-10-26 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of treating microbial infections |
US20080177217A1 (en) * | 2004-05-14 | 2008-07-24 | Hans-Dietrich Polaschegg | Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation |
JP6863973B2 (en) * | 2015-10-07 | 2021-04-21 | コーメディクス・インコーポレーテッド | Taurolidine skin penetration formulation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2618666A1 (en) * | 1975-04-28 | 1976-11-18 | Gaba Ag | NEW ORAL AND DENTAL CARE PRODUCTS |
GB1557163A (en) * | 1975-06-24 | 1979-12-05 | Geistlich Soehne Ag | Dental care preparations |
EP0139534A2 (en) * | 1983-10-20 | 1985-05-02 | Ed. Geistlich Söhne Ag Für Chemische Industrie | Compositions for the prophylactic treatment of osteitis and osteomyelitis |
EP0521225A1 (en) * | 1991-07-04 | 1993-01-07 | Hawe Neos Dental Dr. H. v. Weissenfluh SA | Pharmaceutical preparation for treatment of periodontitis, containing clavulanic acid |
-
1992
- 1992-07-30 GB GB929216155A patent/GB9216155D0/en active Pending
-
1993
- 1993-07-29 EP EP93917947A patent/EP0652753A1/en not_active Ceased
- 1993-07-29 CA CA002141056A patent/CA2141056C/en not_active Expired - Lifetime
- 1993-07-29 WO PCT/GB1993/001607 patent/WO1994003174A1/en not_active Application Discontinuation
- 1993-07-29 JP JP6505094A patent/JPH07509483A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2618666A1 (en) * | 1975-04-28 | 1976-11-18 | Gaba Ag | NEW ORAL AND DENTAL CARE PRODUCTS |
GB1557163A (en) * | 1975-06-24 | 1979-12-05 | Geistlich Soehne Ag | Dental care preparations |
EP0139534A2 (en) * | 1983-10-20 | 1985-05-02 | Ed. Geistlich Söhne Ag Für Chemische Industrie | Compositions for the prophylactic treatment of osteitis and osteomyelitis |
EP0521225A1 (en) * | 1991-07-04 | 1993-01-07 | Hawe Neos Dental Dr. H. v. Weissenfluh SA | Pharmaceutical preparation for treatment of periodontitis, containing clavulanic acid |
Non-Patent Citations (6)
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012184274A (en) * | 1994-12-12 | 2012-09-27 | Omeros Corp | Irrigation solution and method for suppressing pain, inflammation and convulsion |
JP2009024022A (en) * | 1994-12-12 | 2009-02-05 | Omeros Corp | Irrigation solution and method for inhibition of pain, inflammation and spasm |
JP2007031454A (en) * | 1994-12-12 | 2007-02-08 | Omeros Corp | Irrigation solution and method for inhibition of pain, inflammation and spasm |
JPH10510540A (en) * | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ,インコーポレーテッド | Irrigation solutions and methods for controlling pain, inflammation and convulsions |
JP2000501729A (en) * | 1995-12-12 | 2000-02-15 | オメロス メディカル システムズ,インコーポレーテッド | Vascular irrigation solution and method for controlling pain, inflammation, convulsions and restenosis |
JP2008094855A (en) * | 1995-12-12 | 2008-04-24 | Omeros Corp | Vascular irrigation solution for and method for suppressing pain, inflammation, spasm and restenosis |
EP0928187A4 (en) * | 1996-06-24 | 2002-10-02 | Bio Safe Entpr Inc | Antibacterial composition |
EP0928187A1 (en) * | 1996-06-24 | 1999-07-14 | Bio-Safe Enterprises, Inc. | Antibacterial composition |
WO2000001391A1 (en) * | 1998-07-02 | 2000-01-13 | Biolink Corporation | Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof |
US6964959B2 (en) | 1999-12-06 | 2005-11-15 | Carter Wallace, Inc. | Use of a methylol-containing compound to treat tumors |
WO2001039762A2 (en) * | 1999-12-06 | 2001-06-07 | Rhode Island Hospital, A Lifespan Partner | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
WO2001039763A2 (en) * | 1999-12-06 | 2001-06-07 | Rhode Island Hospital, A Lifespan Partner | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
EP2332542A3 (en) * | 1999-12-06 | 2011-09-28 | Geistlich Pharma AG | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
EP1797884A3 (en) * | 1999-12-06 | 2010-02-10 | Geistlich Pharma AG | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
US6429224B1 (en) | 1999-12-06 | 2002-08-06 | Rhode Island Hospital, A Lifespan Partner | Use of taurolidine to treat tumors |
US6995164B2 (en) | 1999-12-06 | 2006-02-07 | Rhode Island Hospital | Methods of treating tumors |
AU784538B2 (en) * | 1999-12-06 | 2006-04-27 | Geistlich Pharma Ag | Use of methylol-containing compounds to treat tumors |
WO2001039763A3 (en) * | 1999-12-06 | 2002-07-11 | Rhode Island Hosp Lifespan Ptr | Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
WO2001039762A3 (en) * | 1999-12-06 | 2002-05-02 | Rhode Island Hosp Lifespan Ptr | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
US7479505B2 (en) | 1999-12-06 | 2009-01-20 | Geistlich Phama Ag | Use of taurolidine to treat tumors |
US6521616B2 (en) | 1999-12-06 | 2003-02-18 | Rhode Island Hospital, A Lifespan Partner | Methods of treating tumors with taurolidine |
US6753328B2 (en) | 2001-10-01 | 2004-06-22 | Rhode Island Hospital | Methods of inhibiting metastases |
WO2004058193A1 (en) * | 2002-12-20 | 2004-07-15 | 3M Espe Ag | Dental material containing bacteriostatic and/or bactericidal substances |
EP1442753A1 (en) * | 2003-02-03 | 2004-08-04 | Polaschegg, Hans-Dietrich, Dr.techn. | Composition for the prevention of indwelling device related infection |
US9339036B2 (en) | 2004-11-02 | 2016-05-17 | Nd Partners, Llc | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
US8933147B2 (en) | 2005-11-17 | 2015-01-13 | 3M Innovative Properties Company | Anti-microbial dental impression material |
WO2012042349A1 (en) * | 2010-09-27 | 2012-04-05 | Geistlich Pharma Ag | Antimicrobial dental care preparation |
US8852617B2 (en) | 2010-09-27 | 2014-10-07 | Geistlich Pharma Ag | Antimicrobial dental care preparation |
AU2011309832B2 (en) * | 2010-09-27 | 2015-01-15 | Geistlich Pharma Ag | Antimicrobial dental care preparation |
US11738120B1 (en) | 2022-04-14 | 2023-08-29 | Cormedix Inc. | Synthesis of taurolidine, purity profiles and polymorphs |
Also Published As
Publication number | Publication date |
---|---|
CA2141056C (en) | 2005-02-15 |
GB9216155D0 (en) | 1992-09-09 |
JPH07509483A (en) | 1995-10-19 |
CA2141056A1 (en) | 1994-02-17 |
EP0652753A1 (en) | 1995-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2141056C (en) | Treatment of dentoalveolar infections with taurolidine and/or taurultam | |
AU716540B2 (en) | New pharmaceutical composition with anaesthetic effect | |
KR101337578B1 (en) | Mucoadhesive xyloglucan―containing formulations useful in medical devices and in pharmaceutical formulations | |
US5160737A (en) | Liquid polymer composition, and method of use | |
CN110996891B (en) | Gel comprising chlorhexidine | |
JP2022164947A (en) | Hypertonic antimicrobial therapeutic composition | |
US5902110A (en) | Bone regeneration | |
PL209943B1 (en) | Use of quinolonyl- and quinolizine derivatives as chemical therapeutic agents | |
US6488912B1 (en) | Treatment of dentoalveolar infections with taurolidine and/or taurultam | |
AT15430U1 (en) | Dental agent based on hyaluronan and octenidine dihydrochloride | |
FR2618670A1 (en) | Medicinal preparation based on essential oils, as well as toothpaste and chewing gum containing it | |
Alpan et al. | Ozone in dentistry | |
RU2184538C2 (en) | Use of dichlorobenzyl alcohol for preparing medicinal agent for treatment of topical inflammation and medicinal agent comprising dichlorobenzyl alcohol | |
Nariman et al. | Clinical efficacy of hyaluronic acid in post-extraction sockets of impacted mandibular third molar | |
EP3914258B1 (en) | A composition for the treatment of periodontitis and regeneration of interdental papilla | |
US20140303101A1 (en) | Compositions for dental care | |
RU2809005C1 (en) | Oral care product containing hexapeptide and chlorhexidine | |
RU2330645C2 (en) | Method of periodontitis treatment | |
RU2761303C1 (en) | Method for obtaining a pharmaceutical composition and a pharmaceutical composition for the treatment and prevention of periodontal diseases | |
JP2895343B2 (en) | Treatment for occlusal trauma | |
JPS62273910A (en) | Composition for oral cavity | |
UA125272C2 (en) | Agent in the form of gel composition “benzidaflaziverdin” with prolonged action for the treatment of periodontal diseases | |
Sood et al. | Efficacy of biodegradable xanthan based chlorhezidine gel (Chlosite®) and 0.2% chlorhexidine irrigation following scaling and root planing for the treatment of chronic periodontitis | |
JPH0764732B2 (en) | Remedy for toothache and pulpitis | |
MXPA97009941A (en) | New pharmaceutical composition with anesthesia effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2141056 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993917947 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 374722 Country of ref document: US Date of ref document: 19950215 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1993917947 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1993917947 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993917947 Country of ref document: EP |